Interestingly, weight loss induces remodeling of cholesterol metabolism pathways in monocytes, including the downregulation of SQLE expression, suggesting that SQLE may be a potential therapeutic target for obesity-associated T2DM. The gene discussed is SQLE; the disease is obesity disorder.